1,059
Participants
Start Date
November 30, 2020
Primary Completion Date
December 31, 2023
Study Completion Date
July 23, 2025
V503
9-valent vaccine, HPV 6/11/16/18/31/33/45/52/58, L1 virus-like particle (VLP) 30/40/60/40/20/20/20/20/20 mcg per dose.
Placebo
0.9% sodium chloride (NaCL)
Umeyama Clinic ( Site 6406), Takasaki
Association of Healthcare Corporation Koukankai Koukan Clinic ( Site 6424), Kawasaki
Ocean Clinic ( Site 6407), Yokohama
Kanno Clinic ( Site 6402), Sakai
P-One Clinic, Keikokai Medical Corp. ( Site 6419), Hachiōji
Iwasa Clinic ( Site 6411), Osaka
Nomura Clinic Namba ( Site 6405), Osaka
Medical Corporation Seiwakai Hayakawa Clinic ( Site 6409), Osaka
Yamanaka Clinic ( Site 6410), Osaka
Doujin Memorial Medical Foundation, Meiwa Hospital ( Site 6404), Tokyo
Yuge Clinic ( Site 6421), Tokyo
Taisei Clinic ( Site 6403), Tokyo
Mildix Skin Clinic ( Site 6423), Tokyo
Sugisawa Dermatology Clinic ( Site 6422), Tokyo
Medical Corporation Sanshikai Toru Clinic ( Site 6401), Tokyo
Medical Corporation Mori to Umi Tokyo Tokyo Kamata Hospital ( Site 6418), Tokyo
Seiyukai Medical Corporation Itoh Skin Clinic ( Site 6416), Tokyo
Naoko Dermatology Clinic ( Site 6417), Tokyo
Medical Corporation Iseikai My City Clinic ( Site 6414), Tokyo
Shinjuku Higashiguchi Clinic ( Site 6415), Tokyo
Ogikuboekimae Clinic ( Site 6413), Tokyo
Kusunoki Clinic ( Site 6412), Tokyo
Merck Sharp & Dohme LLC
INDUSTRY